Jodele S, Sabulski A. Reeling in complement in transplant-associated thrombotic microangiopathy: You’re going to need a bigger boat. Am J Hematol. 2023;98:S57–S73. https://doi.org/10.1002/ajh.26872.

Article  PubMed  Google Scholar 

Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124:645–53. https://doi.org/10.1182/blood-2014-03-564997.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transpl. 2021;56:1805–17. https://doi.org/10.1038/s41409-021-01283-0.

Article  Google Scholar 

Yang J, Xu X, Han S, Qi J, Li X, Pan T, et al. Comparison of multiple treatments in the management of transplant‑related thrombotic microangiopathy: a network meta‑analysis. Ann Hematol. 2023;102:31–39. https://doi.org/10.1007/s00277-022-05069-2.

Article  PubMed  Google Scholar 

Ye Y, Zheng W, Wang J, Hu Y, Luo Y, Tan Y, et al. Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. Hematol Oncol. 2017;35:821–7. https://doi.org/10.1002/hon.2310.

Article  PubMed  CAS  Google Scholar 

Vasu S, Zhao Q, Miller EG, Elder P, Langenberg L, Cataland S, et al. High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: a prospective MIDAS Consortium study. Blood. 2025;146:638–46. https://doi.org/10.1182/blood.2025028390.

Article  PubMed  CAS  Google Scholar 

Abou-Ismail MY, Kapoor S, Sridhar DC, Nayak L, Ahuja S. Thrombotic microangiopathies: An illustrated review. Res Pract Thrombosis Haemost. 2022;6:e12708. https://doi.org/10.1002/rth2.12708.

Article  CAS  Google Scholar 

Jiang S, Qi J, Pan T, Yao Z, Lu S, Han Y, et al. KLF4 overexpression protects against complement-mediated endothelial injury in transplant-associated thrombotic microangiopathy. Haematologica. 2025. https://doi.org/10.3324/haematol.2025.287676.

Article  PubMed  PubMed Central  Google Scholar 

Schoettler ML, French K, Harris A, Bryson E, Deeb L, Hudson Z, et al. D-dimer and sinusoidal obstructive syndrome-novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study. Am J Hematol. 2024;99:370–9. https://doi.org/10.1002/ajh.27186.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Acosta-Medina AA, Sridharan M, Go RS, Moyer AM, Leung N, Willrich MAV, et al. Clinical Outcomes and Treatment Strategies of Adult Transplant-Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High-Risk Criteria. Am J Hematol. 2025;100:830–9. https://doi.org/10.1002/ajh.27651.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA. Transplant-associated thrombotic microangiopathy: opening Pandora’s box. Bone Marrow Transpl. 2017;52:1355–60. https://doi.org/10.1038/bmt.2017.39.

Article  CAS  Google Scholar 

Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021). Zhonghua Xue Ye Xue Za Zhi. 2021;42:177–84.

Google Scholar 

Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, et al. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transpl Cell Ther. 2023;29:151–63. https://doi.org/10.1016/j.jtct.2022.11.015.

Article  CAS  Google Scholar 

Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020;135:1049–57. https://doi.org/10.1182/blood.2019004218.

Article  PubMed  PubMed Central  Google Scholar 

Dvorak CC, Higham C, Shimano KA. Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management. Front Pediatr. 2019;7:133 https://doi.org/10.3389/fped.2019.00133. eCollection 2019.

Article  PubMed  PubMed Central  Google Scholar 

Schoettler ML, Bhatt H, Vasu S. A systematic review of diagnostic, prognostic, and risk blood and urine biomarkers of transplant-associated thrombotic microangiopathy. Front Immunol. 2023;13:1064203. https://doi.org/10.3389/fimmu.2022.1064203.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yoon SH, Kang SH, Kim H, Choi ES, Im HJ, Koh K-N. Incidence, risk factors, and outcomes of transplant-associated thrombotic microangiopathy in pediatric patients after allogeneic hematopoietic cell transplantation: a single-institution prospective study. Bone Marrow Transpl. 2025;60:447–57. https://doi.org/10.1038/s41409-024-02506-w.

Article  CAS  Google Scholar 

Lax N, Davidovits M, Chodick G, Bernfeld Y, Peled O. Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center. Front Pharmacol. 2025;16:1535407. https://doi.org/10.3389/fphar.2025.1535407.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jodele S, Dandoy CE, Aguayo-Hiraldo P, Lane A, Teusink-Cross A, Sabulski A, et al. A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation–associated TMA. Blood. 2024;143:1112–23. https://doi.org/10.1182/blood.2023022526.

Article  PubMed  CAS  Google Scholar 

Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv. 2022;6:1454–63. https://doi.org/10.1182/bloodadvances.2021006523.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang L-P, Zhao P, Wu Y-J, Fu H-X, He Y, Mo X-D, et al. Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study. Bone Marrow Transpl. 2022;57:554–61. https://doi.org/10.1038/s41409-022-01581-1.

Article  CAS  Google Scholar 

Higham CS, Shimano KA, Kharbanda S, Chu J, Cisneros GS, Winestone LE, et al. Cyclophosphamide and Thiotepa Increases Risk of Transplant-Associated Thrombotic Microangiopathy. Transpl Cell Ther. 2024;30:931.e931–931.e910. https://doi.org/10.1016/j.jtct.2024.06.020.

Article  CAS  Google Scholar 

Ma S, Bhar S, Guffey D, Kim RB, Jamil M, Amos CI, et al. Prospective Clinical and Biomarker Validation of the American Society for Transplantation and Cellular Therapy Consensus Definition for Transplantation-Associated Thrombotic Microangiopathy. Transpl Cell Ther. 2023;29:685.e681–685.e687. https://doi.org/10.1016/j.jtct.2023.08.015.

Article  CAS  Google Scholar 

Schoettler ML, Ofori J, Bryson E, Spencer K, Qayed M, Stenger E, et al. Real-World Application of Recently Proposed ASTCT/CIBMTR/EBMT/APBMT Consensus Risk Stratification for Transplantation-Associated Thrombotic Microangiopathy in Children. Transpl Cell Ther. 2024;30:929.e921–929.e926. https://doi.org/10.1016/j.jtct.2024.06.017.

Article  CAS  Google Scholar 

Schoettler ML, Gavriilaki E, Carreras E, Bo-Kyoung C, Dandoy CE, Ho VT, et al. An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy. Transpl Cell Ther. 2025. https://doi.org/10.1016/j.jtct.2025.05.028. Online ahead of print.

Article  Google Scholar 

Styczynski J, Velden Wvd, Fox CP, Engelhard D, Camara Rdl, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803–11. https://doi.org/10.3324/haematol.2016.144428.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, et al. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lacet Infect Dis. 2025;25:e451–e462. https://doi.org/10.1016/S1473-3099(25)00069-6.

Article  CAS  Google Scholar 

Law N, Logan C, Taplitz R. EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes. Viruses. 2024;16:1294 https://doi.org/10.3390/v16081294.

Article